CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma

Blood Cancer J. 2025 May 2;15(1):83. doi: 10.1038/s41408-025-01284-y.
No abstract available

Publication types

  • Letter